Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of APD418 in heart failure with reduced ejection fraction
2020-006131-10Phase 2Completed
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) and Acute Heart Failure (AHF) comparing APD418 with Placebo (2 arms). Primary endpoint: Change in cardiac index. Started May 2021; status: completed.
02
Drugs
APD418
03
Conditions
heart failure with reduced ejection fraction (HFrEF)Acute Heart Failure (AHF)
Beyond the preview
Go deeper on 2020-006131-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006131-10.